Exclusive: Novartis reports two deaths in children after Zolgensma treatments; Lilly's statement on Indiana's abortion law

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Novartis reports two children died from acute liver failure after treatment with Zolgensma gene therapy By Ed Silverman Kayana Szymczak for STAT "It is not a new safety signal and we firmly believe in the overall favorable risk/benefit profile," a Novartis spokesperson said. Read More 'Window dressing': Eli Lilly's after-the-fact statement on Indiana's abortion law sends a disingenuous message By Ed Silverman Businesses tried to convince Indiana lawmakers not to proceed with an abortion ban. Eli Lilly only decried the bill after it became law. Read More STAT+: Wyden wants details on Amgen's U.S. taxes as part of expanding probe into pharma practices By Ed Silverman J. Scott Applewhite/AP “The exact methods by which Amgen is able to achieve such low tax rates are unclear," Sen. Ron Wyden wrote to the company. Read More Sponsor content by STAT Events Healing Medicine's Ailments: The 2022 STAT Summit This November, come for two days of silo-breaking and solution-focused discussions of the most important topics in health care with speakers from Pfizer, the White House, the NIH and more! And, to join us live in Boston, apply for an Attendee Pass upgrade at checkout. Learn More. STAT+: The FDA's 'breakthrough' medical devices are finally hitting the market in numbers By Katie Palmer Jacquelyn Martin/AP FDA authorizations of breakthrough medical devices are accelerating in 2022, with 11 authorized in the first half of the year. Read More Listen: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing By Damian Garde and Allison DeAngelis and Adam Feuerstein STAT's Jason Mast joins us to discuss Jim Wilson, a pioneering scientist who staffers say presided over a toxic, abusive workplace. Read More Thursday, August 11, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser